Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I Study to Assess the Safety, Cell Kinetics and Clinical Activity of Multiple Doses of CYAD-101, Administered Concurrently With the FOLFOX Treatment in Patients With Unresectable Metastatic Colorectal Cancer

Trial Profile

An Open-label, Phase I Study to Assess the Safety, Cell Kinetics and Clinical Activity of Multiple Doses of CYAD-101, Administered Concurrently With the FOLFOX Treatment in Patients With Unresectable Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs CYAD 101 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms alloSHRINK
  • Sponsors Celyad
  • Most Recent Events

    • 30 Nov 2018 According to a Celyad media release, first patient has been dosed in this study. Top-line data is expected in the second half of 2019.
    • 30 Nov 2018 Planned End Date changed from 18 Oct 2034 to 18 Oct 2033.
    • 30 Nov 2018 Planned primary completion date changed from 18 Oct 2021 to 28 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top